NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $89.94 -0.21 (-0.23%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$88.30▼$90.3950-Day Range$78.36▼$90.1552-Week Range$76.53▼$121.39Volume654,893 shsAverage Volume692,243 shsMarket Capitalization$21.38 billionP/E Ratio179.88Dividend YieldN/APrice Target$109.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside21.3% Upside$109.09 Price TargetShort InterestHealthy1.30% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.34Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.80) to ($2.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector635th out of 910 stocksBiological Products, Except Diagnostic Industry103rd out of 155 stocks 3.3 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.30% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in BioNTech has recently decreased by 1.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BioNTech is 306.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BioNTech's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 2.4 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BioNTech this week, compared to 9 articles on an average week.Search Interest30 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($2.80) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 179.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 179.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesAugust 19, 2024 | marketbeat.comModerna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (BNTX)Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.August 12, 2024 | marketbeat.comNovavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (BNTX)Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 6 at 5:21 PM | benzinga.comModerna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study ShowsSeptember 5 at 7:15 AM | globenewswire.comBioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024September 4 at 9:01 AM | finance.yahoo.comTempus Announces Real World Data Collaboration with BioNTechSeptember 4 at 9:01 AM | markets.businessinsider.comTempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology PipelineSeptember 3, 2024 | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 3, 2024 | msn.comUK, Taiwan Approve Moderna's Updated COVID-19 ShotSeptember 3, 2024 | marketwatch.comBioNTech SE ADR outperforms market despite losses on the daySeptember 3, 2024 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) versus BioNTech (NASDAQ:BNTX) Head to Head ComparisonAugust 30, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for BioNTech SE Lifted by Analyst (NASDAQ:BNTX)August 29, 2024 | americanbankingnews.comFY2024 EPS Estimates for BioNTech SE (NASDAQ:BNTX) Reduced by HC WainwrightAugust 28, 2024 | americanbankingnews.comBioNTech's (BNTX) Buy Rating Reaffirmed at HC WainwrightAugust 27, 2024 | finance.yahoo.comBioNTech initiates global trials of mRNA-based lung cancer vaccineAugust 27, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on BioNTech SE (BNTX)August 27, 2024 | markets.businessinsider.comBuy Rating for BioNTech SE: FDA Approval and Advancements in mRNA Vaccine PipelineSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$109.09 High Stock Price Target$171.00 Low Stock Price Target$85.00 Potential Upside/Downside+21.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio179.88 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins-18.69% Pretax Margin-8.75% Return on Equity-2.54% Return on Assets-2.24% Debt Debt-to-Equity Ratio0.01 Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$2.69 billion Price / Sales7.95 Cash Flow$5.17 per share Price / Cash Flow17.40 Book Value$86.38 per share Price / Book1.04Miscellaneous Outstanding Shares237,726,000Free Float192,083,000Market Cap$21.38 billion OptionableOptionable Beta0.23 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $823.67kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $846.46kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $817.16kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $612.05kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInstitutional OwnershipSanctuary Advisors LLCBought 2,558 shares on 9/5/2024Ownership: 0.001%Granite Bay Wealth Management LLCBought 18,459 shares on 8/21/2024Ownership: 0.008%Truist Financial CorpSold 678 shares on 8/21/2024Ownership: 0.007%Employees Retirement System of TexasBought 4,115 shares on 8/15/2024Ownership: 0.013%Millennium Management LLCSold 2,800 shares on 8/15/2024Ownership: 0.000%View All Institutional Transactions BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has decreased by 14.8% and is now trading at $89.94. View the best growth stocks for 2024 here. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) posted its quarterly earnings results on Monday, August, 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by $1.34. The firm's revenue for the quarter was down 23.3% on a year-over-year basis. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. Does BioNTech have any subsidiaries? BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others. When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? Top institutional shareholders of BioNTech include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:BNTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
